initi outperform target price
expect get back track believ attract
price high-qual turnaround stori expect outperform
univers driven fundament recov investor confid
margin expans improv growth disciplin
deliv bp margin improv sinc track
deliv anoth bp bil plan growth
new product view driven margin expans growth profil
improv patient disciplin approach strateg invest
disappoint bax deliveri busi issu initi
misdiagnos result slower growth slightli longer resolut
timelin said beat consensu ep estim rais ep
guidanc year revis long-term organ sale growth
outlook believ
achiev potenti beatabl ex-m
new product multipl geographi plan year
launch would span bax six major busi line
plan bil focus deliveri renal pharma near
term expect stabil suppli volum nutrit large-volum
parenter array on-going new product launch
europ japan drive continu solid execut share perform
valuat target price base ebitda
bil in-lin current multipl impli maintain
price-to-earnings ntm also consist current level risk
includ key product delay failur progress lrp goal growth
margin potenti new litig regulatori qualiti issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc global manufactur provid
diversifi healthcar suppli equip area renal
hospit product
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
initi coverag outperform target price
believ stock attract current level outperform rate base
fundament driver view manag abl demonstr
investor next sever quarter taken necessari step remedi
issu result disappoint
happen manag
compani work suppli disrupt relat hurrican maria last year
number key product line med deliveri nutrit affect brunt
surpris disappoint area large-volum parenter
lvp deliveri iv solut small-volum parenter svp also iv
solut nutrit
lvp caus largest surpris disappoint essenti due misread
strength end market growth util instead
purchas safeti stock distributor custom histor
difficulti access suffici suppli product miss
revenu nutshel stock purchas began destock channel
expos miscalcul expect full-year growth
busi issu rais question volatil trade environ dent street
confid highli regard manag team pleas see follow page
detail discuss issu
manag put new leadership place key busi miss mark
perform detail review continu see healthi end-market
growth opportun put lvp svp nutrit back track low-single-
mid-single-digit growth combin tighter manag execut
competit win-back return among provid normal use
svp iv deliveri nutrit versu interim practic compani put place
past three four quarter manag around tighter suppli product
across market
fundament remain placemargin expans improv growth
disciplin deliveri nutrit issu asid baxter manag team
continu execut multi-year valu creation plan base margin improv
growth profil improv patient disciplin approach strateg invest
deliv bp margin improv sinc track
view deliv anoth bp well bil plan growth
new product also note manag revis long-rang plan lrp
base event lrp object assum addit
 front believ manag remain activ evalu potenti
invest patient disciplin term execut
new product multipl geographi come year
launch span bax six major busi line plan bil focus
deliveri renal pharma near term expect stabil suppli
volum nutrit lvp array recent forthcom new product
launch europ japan drive continu solid execut share
detail see industri report disrupt alpha publish today
valuat target price rate anticip execut lrp disciplin
accret target price base ev/ebitda multipl
ebitda estim bil multipl roughli in-lin stock current
multipl project ebitda estim bil
failur resolv issu medic deliveri nutrit could
neg impact price perform sharehold return
failur show progress toward long-term could
materi advers impact price perform sharehold return
potenti delay failur clinic timelin regulatori approv
reimburs pipelin product failur execut pipelin opportun
expand geograph may result compani fail achiev long-term
financi strategi compani product becom obsolet custom switch
competit product could materi impact compani
revenu profit
new fda quality-rel issu extend remedi exist fda
warn letter warn letter could result signific modif compani
oper potenti recal inabl obtain futur pre-market approv
remov current product market result addit remedi cost
potenti delay disrupt product approv avail
bax challeng deliveri nutrit
structur transitori
investor surpris disappoint sale shortfal deliveri
nutrit part appear though could least partial
avoid stock destock large-volum parenter lvp said
expect issu resolv next sever quarter see
impact long-term prospect busi context medic deliveri
constant currenc cc nutrit declin cc vs
consensu expect busi low-singl digit herein outlin
view key issu
disappoint miss lvp destock issu volum trend unwind
return normal rate come quarter believ lvp issu
primarili distributor destock forecast issu sale lvp deliv robust
growth first five month driven increas purchas due
industry-wid suppli constraint coupl intens flu season
demand suppli result bax custom purchas avail iv solut
compani built forecast elev run rate without
compani creat addit flexibl suppli chain yearli
alloc limit lvp owe capac north cove ireland mexico plant
histor limit amount lvp custom could purchas ensur
adequ suppli custom addit compani assumpt increment
bed gain fell short expect manag taken assumpt
plan context sign bed past five year longer
view reason run rate
overal bax share lvp remain stabl howev inventori destock
sign new account take longer expect expect resolv
next month custom work inventori build accord
compani end-us demand lvp grow ahead market grow
compani lost custom
note lvp intraven solut usual suppli volum least ml
use correct electrolyt fluid imbal vehicl administ
drug estim busi mil
suppli constraint svp expect return normal expect
regain lost small-volum parenter svp busi start address
issu pertain protocol chang shift competit product issu
associ svp relat suppli chain disrupt due hurrican maria
result hurrican compani unabl suppli distribut partner
adequ stock svp
protocol chang account half impact led
temporari shift iv push drug administr address altern practic
drug administr expect compani highlight benefit associ
mini-bag mini-bag iv push includ safeti reduc potenti
medic error higher infect rate relat iv push expect
shift iv push last long given bax technolog advantag
secondli result constrain suppli custom move competit
product account slightli half impact busi sinc product
volum suppli return prehurrican suppli level mini-bag mini-
bag product believ part busi also come back quickli owe
hospit contract volum commit favor price etc
note svp intraven solut usual ml less bax svp
liquid use deliv medic packag small plastic bag estim
size svp busi mil
nutrit also believ issu bax nutrit busi temporari
expect take longer resolv lvp svp bax
nutrit busi market contract compani experienc share loss
result hurricane-rel suppli constraint includ provid delay start
parenter nutrit reduc dosag expect work dilig
american societi parenter enter nutrit aspen help custom
revert appropri feed protocol establish aspen believ
protocol chang take longer resolv confid suppli rebuild
rebas busi expect market return low-single-digit growth
in-lin compani long-term outlook next quarter
infus pump final infus pump compani anticip gain share
 recent launch sigma spectrum pump howev sell
cycl lengthen lower expect infus pump back half
product push earli
invest strateg
type size deal like
expect continu activ evalu opportun howev
believ continu select patient disciplin target deal
gener sharehold valu accret growth margin import
note manag transpar continu activ interest
identifi opportun strateg invest compani long-term plan
conting upon invest see baxter oper execut disciplin
financi manag extens pipelin new product adequ
meet exceed compani long-term object
said manag made number comment regard
 size-agnost open market cap
view aggreg fairli consist view support
follow assess figur manag said subject
execut date paramet long-run plan object
figur select manag commentari
time us realli get go
urgenc busi develop size-agnost
deploy capit acquisit posit impact
busi
seem reason think deal equat
size market cap
pursuinglarg acquisit littl
synergist valu compani pursu
acquisit anyth million billion billion
market cap reason think
done front far activ
 front may expect march compani bought two
surgic asset mil preveleak recothrom use
control bleed surgic suit juli bought clari inject
mil april compani acquir wound mil
believ take patient disciplin approach find right
opportun strateg accret
see accret prefer use compani free cash flow
grow bil mention highlight
manag commentari expect disciplin adher compani key criteria
drive categori leadership enter strateg adjac expand
geograph footprint absenc deal meet criteria expect
compani continu buy back share grow dividend
bax long-rang necessarili reli compani
long-rang plan lrp bake assumpt outlin lrp
may provid long-term target top-lin growth oper margin expans ep
free cash flow context see sale compound-annual-growth-rate driven
bp oper growth new product launch geograph expans similarli
estim bp oper margin expans come mix
launch
geograph expans consequ see essenti compani
reach lrp target expect manag remain disciplin front
restor investor confid resolut deliveri
nutrit issu expect recoveri competit loss compani svp
resolut destock lvp key stock driver
oper margin expans key stock driver beat rais margin line
mani case top line well import stock driver past
month sinc almeida name chairman presid earli despit
disappoint expect manag continu execut high level
resolut fda warn letter compani current two fda warn
letter outstand one relat bax clari facil india anoth relat
north carolina puerto rico facil resolut warn letter would eas
concern cost associ remedi modest on-going
overhang relat letter
recent upcom new product launch process launch
sever new product across busi categori estim new
product contribut mil sale mil total
compani expect new product pipelin contribut bil bil
tabl highlight bil bil project new sale
compani also expect anoth mil new product revenu
expect result new molecul new product new registr
kaguya autom periton dialysi system launch march
japan provid greater access renal therapi home
theranova dialyz extend rang molecul
filter blood therapi close repres natur
spectrum iq infus launch canada ensur
bi-direct electron medic record integr help ensur
correct medic deliv patient
commerci launch select countri extracorpor blood
purif submit fda octob launch eu
olimel emea highest protein lowest glucos content
triple-chamb bag market
clinimix hp protein dual-chamb bag
market
tisseel prima syring launch eu fibrin sealant control
bleed surgeri prevent leakag colon anastomos
overview major busi
organ six main segment eight major busi renal care
compris periton dialysi hemodialysi acut therapi medic deliveri
pharmaceut nutrit advanc surgeri pharma partner figur
overview major busi line size geograph mix growth profil
well primari competitor key product
figur sale profit major busi line
sale geographi
profit
figur overview major busi line
conduct hospital/clin
home-bas therapi
therapi treatment renal
diseas kidney failur
infus pump iv system
infus product
inject pharmaceut
pharma dose hospit
tot
phoenix theranova line
homechoic line preiton
dialysi system prismax line
tot
tot
tot
parenter nutrit prodcut
figur overview major busi line contd
intra-op wound
tissu manag product
ceas bleed hemorrhag
tot
compani behalf
tot
assess growth profil compani coverag univers
organ segment defin growth high-growth busi repres near-
term growth driver earn driver includ us periton dialysi
acut therapi advanc surgeri us infus pump clari lifesci
busi aggreg forecast busi grow compound-annual-growth-rate
repres total sale
periton dialysi home base therapi peopl
end-stag renal diseas irrevers kidney failur
continu renal replac therapi treatment
heamostat sealant use ceas bleed
gener inject anesthesia anti-infect
total sale
contribut
estim
in-lin
manag
long-term guidanc
estim coverag univers
figur coverag univers glanc
prioriti anoth
bp om
highest
figur increas margin driven budget oper effici
new product servic ration portfolio manag
figur margin anoth
rais margin group averag
charl martineau univers toronto manag
geograph
expans drive
bil new
revenu
repres
total sale growth
lrp plan
rais
potenti rang
term target size
continu
opportun
accret
growth margin
figur favor margin growth mix driven new product launch
figur rais potenti size still patient disciplin
bax smarket cap
moment seem
almeida chairman ceo
think could take
larger
almeida chairman ceo
recothrom
improv
signific
improv
figur signific growth convers
target rate expect execut lrp disciplin accret
target price base ev/ebitda multipl ebitda
estim bil multipl roughli in-lin stock current multipl
project ebitda estim bil invest thesi base
recoveri recent disappoint continu upward growth trend driven
new product portfolio manag improv oper effici expens
manag activ disciplin strateg invest believ multipl
attract entri point high-qual name low end
histor averag forward ev/ebitda
valuat scenario base ev/ebitda
ebitda bil scenario base high-growth segment
grow core growth grow
valuat grey scenario base ev/ebitda grey
ebitda bil grey scenario base high-growth
segment grow core growth grow
risk target price rate follow
failur resolv issu medic deliveri nutrit compani
unabl effect resolv issu medic deliveri nutrit time
manner could neg impact price perform sharehold return
failur show progress toward long-term compani
long-rang plan lrp present investor confer lay rang
long-term object relat sale growth oper margin ep
compani unabl achiev target includ optim product
portfolio realign cost structur could materi advers impact
price perform sharehold return
potenti delay failur clinic timelin regulatori approv
reimburs pipelin product part lrp compani laid
geograph expans new product sale target bil new
product sale geograph expans expect contribut growth
plan failur execut pipelin opportun expand geograph
may result compani fail achiev long-term financi strategi
compani product becom obsolet custom switch competit
product could materi impact compani revenu
profit unfavor result unforeseen circumst relat
compani clinic program could result delay failur regulatori approv
new product plan modif indic expans exist
product addit chang insur coverag polici reimburs
regulatori chang relat compani product procedur could hurt
compani busi potenti advers event challeng could materi
affect oper cost potenti sale growth compani
new fda quality-rel issu extend remedi exist fda
warn letter bax product regul fda non-compliance
regulatori requir could result potenti warn letter warn letter
could result signific modif compani oper potenti recal
inabl obtain futur pre-market approv remov current product
market remedi warn letter consist comprehens
plan correct action could drawn materi advers effect
compani term addit remedi cost potenti delay
disrupt product approv avail juli fda issu warn
letter compani base inspect clariss facil ahmedabad india
juli current prepar respons warn letter
continu implement correct prevent action includ product recal
compani also receiv warn letter june fda regard
oper process north cove north carolina jayuya puerto rico
facil warn letter address observ relat current
manufactur practic violat two facil attend regulatori
meet fda regard facil
current price emb long-term sale growth expect
assum annual margin improv
ran market-impli scenario use forecast holt dcf
assum annual margin improv solv sale
compound-annual-growth-rate requir justifi current price
sensit tabl figur help quantifi impact increment margin
growth valuat sensit top-lin growth everi increment
ad per share vs per share ad increment margin
current share price
step assum annual margin improv
step solv lt sale compound-annual-growth-rate requir get current price
base cs forecast deriv long term
assumpt market impli expect
valuat sensit top line growth everi
ad increment margin
assumpt methodolog
ebitda margin base cs research assume
annual improv
sale growth base cs research solv
sale compound-annual-growth-rate requir get current price
explicit forecast holt methodolog calcul
termin valu fade return capit growth toward cost
capit growth respect
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
charl martineau univers toronto statement project
sbc opex
prepaid
asset held sale
accum comp inc loss
charl martineau univers toronto figur statement flow
chang work capit
cf oper
chang invest
use invest
chang st debt
chang lt debt
net stock issuanc option
repurchas treasuri stock
financ
effect fx
net chang cash
charl martineau univers toronto compani mention price
